PF 06817024

Drug Profile

PF 06817024

Alternative Names: PF-06817024; PF-6817024

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Biological factors; Skin disorder therapies
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis; Rhinosinusitis

Most Recent Events

  • 02 Aug 2016 Phase-I clinical trials in Atopic dermatitis in USA (unspecified route) (Pfizer pipeline, August 2016)
  • 21 Apr 2016 Pfizer plans a phase I trial for Rhinosinusitis in USA (IV), (SC) (NCT02743871)
  • 01 Apr 2016 Phase-I clinical trials in Rhinosinusitis (In volunteers) in USA (IV and SC) (NCT02743871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top